Compare XBIT & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XBIT | MRCC |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.3M | 100.1M |
| IPO Year | 2015 | 2011 |
| Metric | XBIT | MRCC |
|---|---|---|
| Price | $2.30 | $4.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 45.1K | ★ 152.8K |
| Earning Date | 05-13-2026 | 03-05-2026 |
| Dividend Yield | N/A | ★ 7.83% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.09 | $4.11 |
| 52 Week High | $3.62 | $7.76 |
| Indicator | XBIT | MRCC |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 39.37 |
| Support Level | $2.32 | $4.11 |
| Resistance Level | $2.49 | $4.97 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 66.69 | 30.77 |
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the United States and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants. Its investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through investment in senior secured, unitranche secured and junior secured debt and, to a lesser extent, unsecured subordinated debt and equity investments.